Baseline demographic and clinical characteristics of the study sample
| Characteristic | Group, no. (%)* | ||
|---|---|---|---|
| No chemotherapy (n = 30) | Chemotherapy with no bevacizumab (n = 47) | Chemotherapy with bevacizumab (n = 10) | |
| Median age at time of stent, yr | 75.3 | 68.0 | 55.3 |
| Median BMI | 22.4 | 25.2 | 22.9 |
| Median ECOG performance status | 2 | 1 | 0.8 |
| Median CEA at initial diagnosis or at time of recurrence, μg/L | 90.7 | 56.5 | 25.3 |
| Male sex | 50 (15) | 60 (28) | 50 (5) |
| Nature of obstruction | |||
| Intraluminal | 93 (28) | 85 (40) | 80 (8) |
| Extraluminal | 0 (0) | 2 (1) | 20 (2) |
| Unknown | 7 (2) | 13 (6) | 0 (0) |
| Stage | |||
| Metastatic | 90 (27) | 81 (38) | 100 (10) |
| Local recurrence | 10 (3) | 19 (9) | 0 (0) |
| Primary in situ | 90 (27) | 81 (38) | 80 (8) |
| Peritoneal disease | 27 (8) | 13 (6) | 40 (4) |
| Location of obstruction | |||
| Rectosigmoid | 53 (16) | 72 (34) | 60 (6) |
| Descending colon | 17 (5) | 2 (1) | 10 (1) |
| Transverse colon | 13 (4) | 6 (3) | 10 (1) |
| Splenic flexure | 7 (2) | 9 (4) | 0 (0) |
| Hepatic flexure | 7 (2) | 9 (4) | 0 (0) |
| Ascending colon | 3 (1) | 0 (0) | 20 (2) |
| Radiotherapy (for rectal tumours) | 7 (2) | 11 (5) | 10 (1) |
BMI = body mass index; CEA = carcinoembryonic antigen; ECOG = Eastern Cooperative Oncology Group.
↵* Unless otherwise indicated.